Global Point of Care
Before initiating the test, it is important to first read and closely follow the detailed instructions included in the package. The BinaxNOWTM COVID-19 Antigen Self Test has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).*
Only available in the US. Terms of Sale.
Capture your
results in
NAVICA for
self‑reporting.
Find a test kit (contains 2 tests) at your local retailer.
Complete your test, or help others administer if they require assistance.
Wait 15 minutes and view the results.
Follow the Instructions for Use regarding serial, or repeat, testing.
Capture your results in NAVICA for self‑reporting.
Capture your results in NAVICA for self‑reporting.
Find a test kit (contains 2 tests) at your local retailer.
Complete your test, or help others administer if they require assistance.
Wait 15 minutes and view the results.
Follow the Instructions for Use regarding serial, or repeat, testing.
Capture your results in NAVICA for
self‑reporting.
Find a test kit (contains 2 tests) at your local retailer.
Complete your test, or help others administer if they require assistance.
Wait 15 minutes and view the results.
Follow the Instructions for Use regarding serial, or repeat, testing.
Learn how to use the BinaxNOW COVID-19 Antigen Self Test.
Learn how to use the BinaxNOW COVID-19 Antigen Self Test and store your results in the NAVICA app for self-testing.
*The BinaxNOW™ COVID-19 Antigen Self Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. It has been authorized only for the detection of proteins from SARSCoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
†Abbott conducted a computational analysis of the detection of multiple SARS-COV-2 Strains, including the DELTA and OMICRON variants, and predicts no impact to the performance of our BinaxNOW™ COVID-19 Antigen Self Test.
1. FDA Letter: Revisions Related to Serial (Repeat) Testing for the EUAs of Antigen IVDs. November 1, 2022. Accessed January 26, 2023. https://www.fda.gov/media/162799/download
a leader in rapid point-of-care diagnostics.
©2023 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement | Declaration for California Compliance Law.
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
Abbott - A Leader in Rapid Point-of-Care Diagnostics.
